My Bibliography

select

Pottie K, Greenaway C, Feightner J, Welch V, Swinkels H, Rashid M, Narasiah L, Kirmayer LJ, Ueffing E, MacDonald NE, Hassan G, McNally M, Khan K, Buhrmann R, Dunn S, Dominic A, McCarthy AE, Gagnon AJ, Rousseau C, Tugwell P. Evidence-based clinical guidelines for immigrants and refugees. CMAJ. 2011 Sep 6;183(12):E824-925. doi: 10.1503/cmaj.090313. Epub 2010 Jun 7. PubMed PMID: 20530168; PubMed Central PMCID: PMC3168666.

select

Hudson M, Assayag D, Caron M, Fox BD, Hirsch A, Steele R, Gaudreau-Taillefer R, Tatibouet S, Rudski L, Baron M. Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. Clin Rheumatol. 2013 Oct;32(10):1467-74. doi: 10.1007/s10067-013-2301-8. Epub 2013 Jun 4. PubMed PMID: 23733274.

select

Assayag D, Lee JS, King TE Jr. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires). 2014;74(2):158-65. Review. PubMed PMID: 24736263.

select

Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, Lee JS. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014 Feb;270(2):583-8. doi: 10.1148/radiol.13130187. Epub 2013 Oct 28. PubMed PMID: 24126367; PubMed Central PMCID: PMC4228744.

select

Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology. 2014 May;19(4):493-500. doi: 10.1111/resp.12234. Epub 2013 Dec 26. Review. PubMed PMID: 24372981.

select

Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, Collard HR, Ryerson CJ. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014 Aug;146(2):422-436. doi: 10.1378/chest.13-2626. Review. PubMed PMID: 24576924.

select

Assayag D, Ryerson CJ. Determining respiratory impairment in connective tissue disease-associated interstitial lung disease. Rheum Dis Clin North Am. 2015 May;41(2):213-23. doi: 10.1016/j.rdc.2014.12.003. Epub 2015 Feb 3. Review. PubMed PMID: 25836638.

select

Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE Jr, Koth LL, Lee JS, Ley B, Shum AK, Wolters PJ, Ryu JH, Collard HR. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med. 2015 Aug;109(8):1058-62. doi: 10.1016/j.rmed.2015.06.012. Epub 2015 Jun 24. PubMed PMID: 26140806; PubMed Central PMCID: PMC4522344.

select

Assayag D, Kim EJ, Elicker BM, Jones KD, Golden JA, King TE Jr, Koth LL, Shum AK, Wolters PJ, Collard HR, Lee JS. Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. Respir Med. 2015 Oct;109(10):1326-31. doi: 10.1016/j.rmed.2015.08.010. Epub 2015 Aug 15. PubMed PMID: 26303338.

select

Ryerson CJ, Camp PG, Eves ND, Schaeffer M, Syed N, Dhillon S, Jensen D, Maltais F, O'Donnell DE, Raghavan N, Roman M, Stickland MK, Assayag D, Bourbeau J, Dion G, Fell CD, Hambly N, Johannson KA, Kalluri M, Khalil N, Kolb M, Manganas H, Morán-Mendoza O, Provencher S, Ramesh W, Rolf JD, Wilcox PG, Guenette JA. High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Ann Am Thorac Soc. 2016 Sep;13(9):1640-7. doi: 10.1513/AnnalsATS.201604-267OC. PubMed PMID: 27348402.

select

Johannson KA, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Golden JA, Jones KD, King TE Jr, Koth LL, Lee JS, Ley B, Wolters PJ, Collard HR. A diagnostic model for chronic hypersensitivity pneumonitis. Thorax. 2016 Oct;71(10):951-4. doi: 10.1136/thoraxjnl-2016-208286. Epub 2016 May 31. PubMed PMID: 27245779; PubMed Central PMCID: PMC5530732.

select

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. Eur Respir J. 2017 Aug;50(2). doi: 10.1183/13993003.00936-2017. Print 2017 Aug. PubMed PMID: 28860269.

select

Wang P, Jones KD, Urisman A, Elicker BM, Urbania T, Johannson KA, Assayag D, Lee J, Wolters PJ, Collard HR, Koth LL. Pathologic Findings and Prognosis in a Large Prospective Cohort of Chronic Hypersensitivity Pneumonitis. Chest. 2017 Sep;152(3):502-509. doi: 10.1016/j.chest.2017.02.011. Epub 2017 Feb 20. PubMed PMID: 28223152.

select

Storme M, Semionov A, Assayag D, Lefson M, Kitty D, Dannenbaum D, Torrie J, Lejeune P, Robinson E, Ahmad Khan F. Estimating the incidence of interstitial lung diseases in the Cree of Eeyou Istchee, northern Québec. PLoS One. 2017;12(9):e0184548. doi: 10.1371/journal.pone.0184548. eCollection 2017. PubMed PMID: 28886193; PubMed Central PMCID: PMC5590969.

select

Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. Am J Respir Crit Care Med. 2018 Apr 15;197(8):1036-1044. doi: 10.1164/rccm.201710-1986OC. Epub 2017 Nov 27. PubMed PMID: 29172641; PubMed Central PMCID: PMC6839923.

select

Naderi N, Assayag D, Mostafavi-Pour-Manshadi SM, Kaddaha Z, Joubert A, Ouellet I, Drouin I, Li PZ, Bourbeau J. Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease. Respir Med. 2018 May;138:129-136. doi: 10.1016/j.rmed.2018.03.035. Epub 2018 Apr 5. PubMed PMID: 29724384.

select

Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N Engl J Med. 2018 Dec 6;379(23):2209-2219. doi: 10.1056/NEJMoa1801562. Epub 2018 Oct 20. PubMed PMID: 30345907; PubMed Central PMCID: PMC6371965.

select

Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA. Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. Eur Respir J. 2019 Aug;54(2). doi: 10.1183/13993003.00421-2019. Print 2019 Aug. PubMed PMID: 31097522.

select

Assayag D, Morisset J, Johannson KA, Wells AU, Walsh SLF. Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis. Thorax. 2020 May;75(5):407-412. doi: 10.1136/thoraxjnl-2019-213968. Epub 2020 Feb 13. PubMed PMID: 32054644.

select

Wong AW, Fidler L, Marcoux V, Johannson KA, Assayag D, Fisher JH, Hambly N, Kolb M, Morisset J, Shapera S, Ryerson CJ. Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest. 2020 Sep;158(3):1069-1078. doi: 10.1016/j.chest.2020.04.019. Epub 2020 Apr 22. Review. PubMed PMID: 32333929; PubMed Central PMCID: PMC7194738.

select

Wong AW, Lee TY, Johannson KA, Assayag D, Morisset J, Fell CD, Fisher JH, Shapera S, Gershon AS, Cox G, Halayko AJ, Hambly N, Manganas H, Sadatsafavi M, Wilcox PG, To T, Marcoux V, Khalil N, Kolb M, Ryerson CJ. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respir Res. 2020 Dec 7;21(1):322. doi: 10.1186/s12931-020-01579-7. PubMed PMID: 33287805; PubMed Central PMCID: PMC7720501.

select

Tsai APY, Hur SA, Wong A, Safavi M, Assayag D, Johannson KA, Morisset J, Fell C, Fisher JH, Manganas H, Shapera S, Cox G, Gershon AS, Hambly N, Khalil N, To T, Wilcox PG, Halayko A, Kolb MR, Ryerson CJ. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 2021 Jan;76(1):37-43. doi: 10.1136/thoraxjnl-2020-214944. Epub 2020 Oct 6. PubMed PMID: 33023996.

select

Tran T, Assayag D, Ernst P, Suissa S. Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis: A Population-Based Cohort Study. Chest. 2021 Feb;159(2):673-682. doi: 10.1016/j.chest.2020.08.2080. Epub 2020 Sep 1. PubMed PMID: 32882251.

select

Suissa S, Assayag D. Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?. Eur Respir J. 2021 Mar;57(3). doi: 10.1183/13993003.04562-2020. Print 2021 Mar. PubMed PMID: 33737380.

select

Assayag D. Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go. Ann Am Thorac Soc. 2021 Jul;18(7):1115-1116. doi: 10.1513/AnnalsATS.202102-123ED. PubMed PMID: 34242150; PubMed Central PMCID: PMC8328363.

select

Chen T, Tsai APY, Hur SA, Wong AW, Sadatsafavi M, Fisher JH, Johannson KA, Assayag D, Morisset J, Shapera S, Khalil N, Fell CD, Manganas H, Cox G, To T, Gershon AS, Hambly N, Halayko AJ, Wilcox PG, Kolb M, Ryerson CJ. Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respir Res. 2021 Jul 8;22(1):202. doi: 10.1186/s12931-021-01790-0. PubMed PMID: 34238283; PubMed Central PMCID: PMC8265065.

select

Assayag D, Garlick K, Johannson KA, Fell CD, Kolb M, Cox G, Hambly N, Manganas H, Morisset J, Fisher JH, Shapera S, Gershon AS, To T, Sadatsafavi M, Wilcox PG, Halayko AJ, Khalil N, Ryerson CJ. Treatment Initiation in Patients with Interstitial Lung Disease in Canada. Ann Am Thorac Soc. 2021 Oct;18(10):1661-1668. doi: 10.1513/AnnalsATS.202009-1122OC. PubMed PMID: 33493425.

select

Kawano-Dourado L, Glassberg MK, Assayag D, Borie R, Johannson KA. Sex and gender in interstitial lung diseases. Eur Respir Rev. 2021 Dec 31;30(162). doi: 10.1183/16000617.0105-2021. Print 2021 Dec 31. PubMed PMID: 34789464; PubMed Central PMCID: PMC9489177.

select

Johannson KA, Lethebe BC, Assayag D, Fisher JH, Kolb M, Morisset J, Shapera S, Gershon AS, Hambly N, Khalil N, To T, Fell CD, Cox G, Manganas H, Halayko AJ, Marcoux V, Sadatsafavi M, Wilcox PG, Bertazzon S, Ryerson CJ. Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Ann Am Thorac Soc. 2022 Jan;19(1):20-27. doi: 10.1513/AnnalsATS.202102-216OC. PubMed PMID: 34033739.

select

Adams CJ, Shapera S, Ryerson CJ, Assayag D, Johannson KA, Fell CD, Morisset J, Manganas H, Kolb M, Hambly N, Cox G, Khalil N, Marcoux V, Wilcox PG, To T, Sadatsafavi M, Halayko AJ, Gershon A, Garlick K, Fisher JH. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respir Med. 2022 Jan;191:106722. doi: 10.1016/j.rmed.2021.106722. Epub 2021 Dec 23. PubMed PMID: 34959146.

select

Nakanishi T, Cerani A, Forgetta V, Zhou S, Allen RJ, Leavy OC, Koido M, Assayag D, Jenkins RG, Wain LV, Yang IV, Lathrop GM, Wolters PJ, Schwartz DA, Richards JB. Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study. Eur Respir J. 2022 Feb;59(2). doi: 10.1183/13993003.03979-2020. Print 2022 Feb. PubMed PMID: 34172473; PubMed Central PMCID: PMC8828995.

select

Goobie GC, Ryerson CJ, Johannson KA, Schikowski E, Zou RH, Khalil N, Marcoux V, Assayag D, Manganas H, Fisher JH, Kolb MRJ, Gibson KF, Kass DJ, Zhang Y, Lindell KO, Nouraie SM. Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. Am J Respir Crit Care Med. 2022 Feb 15;205(4):459-467. doi: 10.1164/rccm.202109-2065OC. PubMed PMID: 34818133.

select

Jalbert AC, Siafa L, Ramanakumar AV, Assayag D. Gender and racial equity in clinical research for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur Respir J. 2022 Mar;59(3). doi: 10.1183/13993003.02969-2021. Print 2022 Mar. PubMed PMID: 35058247.

select

Schaeffer MR, Kumar DS, Assayag D, Fisher JH, Johannson KA, Khalil N, Kolb M, Manganas H, Marcoux VS, Guenette JA, Ryerson CJ. Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD. Respir Med. 2022 Mar 5;195:106792. doi: 10.1016/j.rmed.2022.106792. [Epub ahead of print] PubMed PMID: 35272261.

select

Wong AW, Khor YH, Donohoe K, Comes A, Marcoux V, Fisher JH, Johannson KA, Assayag D, Morisset J, Shapera S, Khalil N, Fell CD, Manganas H, Cox G, To T, Gershon AS, Hambly N, Halayko AJ, Sadatsafavi M, Wilcox PG, Kolb M, Richeldi L, Ryerson CJ. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. Ann Am Thorac Soc. 2022 May;19(5):863-867. doi: 10.1513/AnnalsATS.202108-954RL. PubMed PMID: 34898386.

select

Khor YH, Goh NSL, Wong AW, Johannson KA, Marcoux V, Fisher JH, Assayag D, Manganas H, Khalil N, Kolb M, Ryerson CJ. Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. Ann Am Thorac Soc. 2022 Jun;19(6):962-970. doi: 10.1513/AnnalsATS.202108-980OC. PubMed PMID: 35007498.

select

Lok SD, Wong AW, Khor YH, Ryerson CJ, Johannson KA. Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease. Chest. 2022 Jun;161(6):1594-1597. doi: 10.1016/j.chest.2021.12.636. Epub 2021 Dec 16. PubMed PMID: 34921905.

select

Guler SA, Hur SA, Stickland MK, Brun P, Bovet L, Holland AE, Bondarenko J, Hambly N, Wald J, Makhdami N, Kreuter M, Gloeckl R, Jarosch I, Tan B, Johannson KA, McBride SA, De Boer K, Sandoz JS, Sun K, Assayag D, Bhatt SP, Morisset J, Ferraro V, Garvey C, Camp PG, Ryerson CJ. Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. Thorax. 2022 Jun;77(6):589-595. doi: 10.1136/thoraxjnl-2021-217361. Epub 2021 Aug 30. PubMed PMID: 34462346.

select

Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, Chong SG, MacIsaac S, Assayag D, Johannson KA, Fell CD, Marcoux V, Manganas H, Morisset J, Comes A, Fisher JH, Shapera S, Gershon AS, To T, Wong AW, Sadatsafavi M, Wilcox PG, Halayko AJ, Khalil N, Cox G, Richeldi L, Ryerson CJ, Kolb M. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022 Oct;60(4). doi: 10.1183/13993003.02571-2021. Print 2022 Oct. PubMed PMID: 35273032.